Related Experiment Video
Updated: Feb 10, 2026

Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs
Published on: October 31, 2025
Oral diatrizoate acid for meconium-related ileus in extremely preterm infants
Kaori Michikata1, Yuki Kodama1, Masatoki Kaneko1
1Department of Obstetrics and Gynecology, University of Miyazaki, Kiyotake, Miyazaki, Japan.
Insights
Prophylactic oral diatrizoate acid effectively prevented meconium-related ileus (MRI) in extremely preterm infants. This intervention also reduced mortality rates in very premature infants, showing significant benefits.
Area of Science:
- Neonatal Medicine
- Gastroenterology
- Pediatric Surgery
Background:
- Intestinal disorders are a significant concern in extremely preterm infants.
- Meconium-related ileus (MRI) is a serious complication in this vulnerable population.
Purpose of the Study:
- To investigate the efficacy of prophylactic oral Gastrografin (diatrizoate acid) in preventing MRI.
- To assess the impact of this intervention on clinical outcomes in extremely preterm infants.
Main Methods:
- A retrospective case-control study compared extremely preterm infants (<28 weeks gestation) who received prophylactic diatrizoate acid with a matched control group.
- Infants with congenital abnormalities or early mortality were excluded.
- Outcomes analyzed included MRI incidence, time to full enteral feeding, hospital stay duration, and mortality rates.
Main Results:
- No cases of MRI were observed in the prophylactic diatrizoate acid group, compared to six cases in the control group (P = 0.039).
- The prophylactic group experienced a shorter median time to full enteral feeding (22 vs. 25 days) and a shorter hospital stay (126 vs. 142 days).
- Mortality rate for infants aged 24-27 weeks was significantly lower in the prophylactic group (0% vs. 8.2%, P = 0.021).
Conclusions:
- Prophylactic oral diatrizoate acid is effective in reducing MRI in extremely preterm infants.
- The intervention demonstrates a significant reduction in mortality for infants born at 24-27 weeks gestation.
- Oral diatrizoate acid appears to be a beneficial prophylactic measure for extremely preterm infants without observed side-effects.
Background:
Intestinal disorders are common in very low-birthweight infants. The purpose of this study was to evaluate the impact of prophylactic oral Gastrografin® (diatrizoate acid) on meconium-related ileus (MRI) in extremely preterm infants.
Methods:
This was a retrospective case-control study of infants born extremely preterm at <28 weeks of gestation and treated with diatrizoate acid (prophylactic group) or not (control group) in the periods 2007-2014 and 2000-2009, respectively. In the 2007-2014 period, 120 infants received prophylactic diatrizoate acid solution. From the 165 infants in the control group, we selected 120 infants matched for gestational age. Cases of death before 72 h of life or congenital abnormalities were excluded. Intestinal disorders, time until full enteral feeding, duration of hospital stay, mortality rate, and neurodevelopmental outcome were compared.
Results:
MRI occurred in six infants in the control group and in none of the infants in the prophylactic group (P = 0.039). Median time until full enteral feeding was 25 versus 22 days (P < 0.01), hospital stay was 142 versus 126 days (P < 0.01), and mortality rate for infants aged 24-27 weeks was 8.2% versus 0% (P = 0.021), respectively.
Conclusions:
Prophylactic oral diatrizoate acid reduced MRI in extremely preterm infants without side-effects and decreased the mortality rate of infants born at 24-27 weeks, and is thus beneficial in extremely preterm infants.
Related Concept Videos
Absolute and Local Extreme Values
Oral Cavity
Teeth: The teeth are the hardest structures in our bodies. Humans have two sets of teeth throughout their lifetime: deciduous (baby) teeth and permanent teeth. Each tooth consists of several parts: the crown (visible part), the root (embedded in the jaw), enamel (hard outer...
Amino acids
Drug Dosing: Infants and Children
Polyprotic Acids
Oral Hypoglycemic Agents: Glinides

